IPO - Profile

Sensei Biotherapeutics, Inc.

Health Care > Major Pharmaceuticals



We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We are engineering our ImmunoPhage product candidates to directly target antigen presenting cells, or APCs, and modulate the tumor microenvironment, or TME, through the targeted use of nanobodies which further enhances therapeutic activity. We believe our More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$19.00 7,000,000 Positive High 52.72%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 03 Feb, 2021

Offer 04 Feb, 2021

Look Ahead

Lock Up Expiry Aug 04, 2021

IPO Terms

Offer Price $19.00
Offer Size 7M

Market Sentiments

Stock Price